A phase 2 trial (NCT04127227) is ongoing to evaluate PD-1 inhibitors in combination with P-GemOx chemotherapy for advanced NKTCL patients. This evidence concerns the gene PDCD1 and extranodal nasal NK/T cell lymphoma.